Climb Bio Inc (CLYM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $583.86M
Last updated: Nov 17, 2026 at 4:29 PM ET
Climb Bio Inc (CLYM) Statistics
Climb Bio (CLYM) has a market cap of $583.86M and an enterprise value of $544.13M. Its share count is up 17.69% from a year earlier.
Total Valuation
Enterprise value is 6.80% below the market cap, as cash exceeds debt.
| Market Cap | $583.86M |
|---|---|
| Enterprise Value | $544.13M |
| Latest price (Nov 17, 2026) | $9.78 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is up 414.74% over 52 weeks and trades 13.76% below its 50-day average.
| Beta (1Y) | 1.58 |
|---|---|
| 52-Week Change | +414.74% |
| 1-Month Change | +0.51% |
| 3-Month Change | -43.60% |
| 6-Month Change | +1.35% |
| 5-Year Change | -41.16% |
| Total Return (1Y) | +414.74% |
| Total Return (3Y CAGR) | +56.72% |
| Total Return (5Y CAGR) | -11.37% |
| Return vs SPY (1Y) | +400.48% |
| Max Drawdown (1Y) | -50.62% |
| Max Drawdown (3Y) | -88.92% |
| Sharpe Ratio (1Y) | 1.74 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $11.34 |
| 200-Day Average | $10.72 |
| 52-Week Range | $1.64 to $18.33 |
| RSI (14 Days) | 44.1 |
| Average Volume (20 Days) | 1.28M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 26.58x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 26.58x |
|---|---|
| Quick Ratio | 26.58x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -26.01% over the last 12 months, against a 5-year average of -33.67%.
| Return on Equity (ROE) | -26.01% |
|---|---|
| Return on Assets (ROA) | -25.07% |
| ROE (5Y Average) | -33.67% |
| ROA (5Y Average) | -32.48% |
| ROIC (5Y Average) | -33.56% |
Scores
CLYM has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Gross Profit | -$30.00K |
| Operating Income | -$66.76M |
| Pretax Income | -$59.31M |
| Net Income | -$59.31M |
| Reported EPS (TTM) | -$0.82 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 96.40% of the $236.56M in total assets.
| Cash and Equivalents | $39.73M |
|---|---|
| Total Debt | $0 |
| Net Cash | $39.73M |
| Net Cash Per Share | $0.50 |
| Working Capital | $202.24M |
| Shareholder Equity | $228.05M |
| Book Value Per Share | $2.85 |
| Total Assets | $236.56M |
| Total Liabilities | $8.51M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.08M of capital spending, operating cash flow left -$53.64M of free cash flow.
| Operating Cash Flow | -$52.56M |
|---|---|
| Capital Expenditures | $1.08M |
| Free Cash Flow | -$53.64M |
| FCF Per Share | -$0.93 |
| Depreciation and Amortization | $1.96M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -22.24% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -22.24% |
Dividends and Yields
CLYM does not pay a dividend. Its free cash flow yield is -6.85%.
| FCF Yield | -6.85% |
|---|---|
| Buyback Yield | -13.21% |
| Shareholder Yield | -13.21% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CLYM
What is CLYM's market cap?
Climb Bio has a market cap of $583.86M. Its enterprise value, which adds debt and subtracts cash, is $544.13M.
How many shares of CLYM are outstanding?
Climb Bio has 80.03M shares outstanding. The count is up 17.69% from a year earlier.
Does CLYM pay a dividend?
No. Climb Bio does not pay a dividend.
How much debt does CLYM have?
Climb Bio has $0 of total debt and $39.73M of cash and equivalents, a net cash position of $39.73M.
CLYM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors